By Liz Moyer Investing.com -- Lawmakers are once again trying to get caps on prescription drug pricing across the finish line, and that puts insulin in the spotlight. The market for insulin...
By Liz Moyer Investing.com -- U.S. stocks wobbled on Thursday as investors awaited Friday's jobs report for July. Here are the midday movers for Aug. 4: Coinbase Global Inc...
(Updated - August 4, 2022 11:12 AM EDT) Eli Lilly & Co. (NYSE:LLY) shares are down Thursday following its second-quarter earnings report, which saw it miss analyst estimates.The drugmaker...
By Liz Moyer Investing.com -- U.S. stocks opened mixed on Thursday as investors awaited the jobs report for July for hints about the direction of the economy. At 10:02 AM ET, the Dow Jones...
By Peter Nurse Investing.com -- Stocks in focus in premarket trade on Thursday, August 4th. Please refresh for updates. ConocoPhillips (NYSE:COP) stock rose 3.5% after the oil giant raised...
By Peter Nurse Investing.com -- U.S. stocks are seen opening slightly higher Thursday, continuing the previous session’s positive tone ahead of the release of key weekly unemployment...
By Geoffrey Smith Investing.com -- China fires missiles into the sea around Taiwan as it vents its anger at Nancy Pelosi's visit earlier in the week. Alibaba reports earnings amid reports...
Eli Lilly & Co. (NYSE:LLY) reported Q2 EPS of $1.25, $0.46 worse than the analyst estimate of $1.71. Revenue for the quarter came in at $6.49 billion versus the consensus estimate of $6.85...
Investing.com - Eli Lilly (NYSE:LLY) reported on Thursday second quarter {{erl-273||earnings that missed analysts' forecasts and revenue that fell short of expectations. Eli Lilly...
By Oliver Gray Investing.com - U.S. stock futures were trading slightly lower during Wednesday’s evening deals, following a positive close among major benchmark averages amid robust...
The Biden administration and drug maker are in talks to ensure bebtelovimab remains available to people without health insurance.
Catch the Club's "Morning Meeting" livestream at 10:20 a.m. ET every weekday.
By Oliver Gray Investing.com - Dow futures were trading slightly lower during Sunday’s evening deals, after major benchmark indices finished this week significantly higher and...
By Noreen Burke Investing.com -- After data on Thursday showing that the U.S. economy is on the cusp of a recession this Friday’s monthly employment report will be even more highly...
By Liz Moyer Investing.com -- Stocks notched a two-day rally as investors believe the Federal Reserve could slow the pace of interest rate increases after new data showed the economy slowed...
By Senad Karaahmetovic A Morgan Stanley strategist says the ongoing Q2 earnings season is likely a negative catalyst for equities in the coming weeks. The strategist is “skeptical” that...
ERAS-601, a potential best-in-class SHP2 inhibitor, is being investigated alone and in combination in the ongoing FLAGSHP-1 Phase 1/1b trial Erasca previously signed CTCSAs with Lilly and...
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Eli Lilly To Supply Additional 150K Doses Of COVID-19 Treatment To US Government Eli Lilly...
(Reuters) – Eli Lilly and Co said on Wednesday it will supply additional doses of its COVID-19 antibody drug to the U.S. government in order to meet demand through late August.
Eli Lilly & Co. said Wednesday that it will supply the U.S. government with an additional 150,000 doses of its COVID treatment bebtelovimab for about $275 million. Delivery of the doses...
We do not want to be greedy like we were with our oil names. We do not want to make the same mistake twice.
Eli Lilly continues to work on commercializing its strong innovation pipeline, which is a key reason the CNBC Investing Club owns the stock.
Eli Lilly And Co (NYSE: LLY) announced topline results from one-year analyses of the efficacy and safety of lebrikizumab for moderate-to-severe atopic dermatitis (AD). The new findings from...
Eli Lilly And Co (NYSE: LLY) presented new data from a mechanism of action study and new analyses of the global registration program for Mounjaro (tirzepatide) injection at the American...
By Dan Levine and Marisa Taylor (Reuters) – A former human resources officer at Eli Lilly & Co sued the pharmaceutical company on Monday, alleging she was terminated after pointing out...
By Liz Moyer Investing.com -- U.S. stocks are higher on Monday as investors try to turn the mood positive. Here are the midday movers for June 6: DiDi Global Inc ADRs (NYSE:DIDI) surged...
Monday’s additional top analyst upgrades and downgrades were on American Express, Aurora Cannabis, Edison International, Eli Lilly, PayPal, Upwork and more.
These are the stocks posting the largest moves in midday trading.
American television personality and host of Mad Money on CNBC, Jim Cramer, tweeted his optimism about healthcare company Eli Lilly (NYSE: LLY) due to the success of its phase 3 clinical...
By Peter Nurse Investing.com -- Stocks in focus in premarket trade on Monday, May 23rd. Please refresh for updates. VMware (NYSE:VMW) stock soared 23% after the Wall Street Journal reported...
Investing.com – U.S. equities were mixed at the close on Friday, as gains in the Healthcare, Telecoms and Oil & Gas sectors propelled shares higher while losses in the Consumer Goods,...
Morgan Stanley strategist Michelle Weaver introduced the ‘Analyst Top Picks’ list consisting of 45 highest-conviction calls in North America. The list includes the latest and best ideas from...
By Sam Boughedda Investing.com -- Eli Lilly (NYSE:LLY) stock rose over 3% in early Thursday trading after the company reported first-quarter earnings, beating earnings and revenue...
Pre-Open Stock Movers:Teladoc (NYSE:TDOC) 44% LOWER; reported Q1 EPS of ($41.58), which may not compare to the analyst estimate of ($0.56). Revenue for the quarter came in at $565.4 million...
Eli Lilly & Co. (NYSE:LLY) reported Q1 EPS of $2.62, $0.49 better than the analyst estimate of $2.13. Revenue for the quarter came in at $7.81 billion versus the consensus estimate of...
Investing.com - Eli Lilly (NYSE:LLY) reported on Thursday first quarter {{erl-273||earnings that beat analysts' forecasts and revenue that topped expectations. Eli Lilly announced earnings...
Investing.com – U.S. equities were lower at the close on Wednesday, as losses in the Technology, Consumer Services and Basic Materials sectors propelled shares lower. At the close in NYSE,...
By Sam Boughedda Investing.com -- Eli Lilly and Company (NYSE:LLY) is trading 3% higher Wednesday after Morgan Stanley analyst Terence Flynn raised the price target on the stock to $364 from...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
